OUTCOMES OF ALLOGENEIC SC TRANSPLANT IN HEMATOLOGICAL MALIGNANCY PATIENTS USING BUSULFAN 3 (9.6 MG/KG) BASED CONDITIONING REGIMEN

Objective: To study the outcomes of allo-HCT in patients with hematological malignancy who received BU3 (9.6 mg/kg) based conditioning from matched related or unrelated donors. Methodology: A retrospective analysis of KFSHRC- BMT Database, we identified 65 patients who received Allo-HCT between Octo...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Majed Altareb, Yazeed Bajuaifer, Walid Rasheed
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Diseases of the blood and blood-forming organs RC633-647.5
Acceso en línea:	https://doaj.org/article/990786919fe843c4b5cddd2870568c6b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:990786919fe843c4b5cddd2870568c6b
record_format	dspace
spelling	oai:doaj.org-article:990786919fe843c4b5cddd2870568c6b2021-11-10T04:37:05ZOUTCOMES OF ALLOGENEIC SC TRANSPLANT IN HEMATOLOGICAL MALIGNANCY PATIENTS USING BUSULFAN 3 (9.6 MG/KG) BASED CONDITIONING REGIMEN2531-137910.1016/j.htct.2021.10.1051https://doaj.org/article/990786919fe843c4b5cddd2870568c6b2021-11-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2531137921011986https://doaj.org/toc/2531-1379Objective: To study the outcomes of allo-HCT in patients with hematological malignancy who received BU3 (9.6 mg/kg) based conditioning from matched related or unrelated donors. Methodology: A retrospective analysis of KFSHRC- BMT Database, we identified 65 patients who received Allo-HCT between October 2005 and December 2019 at King Faisal Specialist Hospital & Research Center. The patients received SCT from full HLA matched related or unrelated donors. We excluded Mismatched MUD, Cord & Haplo-identical Stem Cell sources. Results: We identified 47 AML (72.3%), 8 MDS (12.3%), 8 Myelofibrosis (12.3%) & 2 CML (3.1%) patients. Acute GvHD grade II-IV and III-IV occurred in 29% and 14% respectively. Chronic GvHD occurred in 55% and was extensive in 24% of patients. With Median follow-up 60.5 months, 2 years and 5 years OS were 58.5 % and 44.1% respectively. The 2 years and 5 years DFS were 52.9% and 44.5% respectively. Cumulative incidence of relapse and NRM at 2- years were 29.5% and 17.4% respectively. Day +100 TRM were 10.7% Conclusion: Allogeneic SCT using BU3 based regimen appears feasible to use in patients who are not suitable for fully myeloablative (BU4) regimen. TRM, DFS & OS rate were comparable to reports from studies using BU4 based regimen, warranting prospective studies in these patients.Majed AltarebYazeed BajuaiferWalid RasheedElsevierarticleDiseases of the blood and blood-forming organsRC633-647.5ENHematology, Transfusion and Cell Therapy, Vol 43, Iss , Pp S48- (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the blood and blood-forming organs RC633-647.5
spellingShingle	Diseases of the blood and blood-forming organs RC633-647.5 Majed Altareb Yazeed Bajuaifer Walid Rasheed OUTCOMES OF ALLOGENEIC SC TRANSPLANT IN HEMATOLOGICAL MALIGNANCY PATIENTS USING BUSULFAN 3 (9.6 MG/KG) BASED CONDITIONING REGIMEN
description	Objective: To study the outcomes of allo-HCT in patients with hematological malignancy who received BU3 (9.6 mg/kg) based conditioning from matched related or unrelated donors. Methodology: A retrospective analysis of KFSHRC- BMT Database, we identified 65 patients who received Allo-HCT between October 2005 and December 2019 at King Faisal Specialist Hospital & Research Center. The patients received SCT from full HLA matched related or unrelated donors. We excluded Mismatched MUD, Cord & Haplo-identical Stem Cell sources. Results: We identified 47 AML (72.3%), 8 MDS (12.3%), 8 Myelofibrosis (12.3%) & 2 CML (3.1%) patients. Acute GvHD grade II-IV and III-IV occurred in 29% and 14% respectively. Chronic GvHD occurred in 55% and was extensive in 24% of patients. With Median follow-up 60.5 months, 2 years and 5 years OS were 58.5 % and 44.1% respectively. The 2 years and 5 years DFS were 52.9% and 44.5% respectively. Cumulative incidence of relapse and NRM at 2- years were 29.5% and 17.4% respectively. Day +100 TRM were 10.7% Conclusion: Allogeneic SCT using BU3 based regimen appears feasible to use in patients who are not suitable for fully myeloablative (BU4) regimen. TRM, DFS & OS rate were comparable to reports from studies using BU4 based regimen, warranting prospective studies in these patients.
format	article
author	Majed Altareb Yazeed Bajuaifer Walid Rasheed
author_facet	Majed Altareb Yazeed Bajuaifer Walid Rasheed
author_sort	Majed Altareb
title	OUTCOMES OF ALLOGENEIC SC TRANSPLANT IN HEMATOLOGICAL MALIGNANCY PATIENTS USING BUSULFAN 3 (9.6 MG/KG) BASED CONDITIONING REGIMEN
title_short	OUTCOMES OF ALLOGENEIC SC TRANSPLANT IN HEMATOLOGICAL MALIGNANCY PATIENTS USING BUSULFAN 3 (9.6 MG/KG) BASED CONDITIONING REGIMEN
title_full	OUTCOMES OF ALLOGENEIC SC TRANSPLANT IN HEMATOLOGICAL MALIGNANCY PATIENTS USING BUSULFAN 3 (9.6 MG/KG) BASED CONDITIONING REGIMEN
title_fullStr	OUTCOMES OF ALLOGENEIC SC TRANSPLANT IN HEMATOLOGICAL MALIGNANCY PATIENTS USING BUSULFAN 3 (9.6 MG/KG) BASED CONDITIONING REGIMEN
title_full_unstemmed	OUTCOMES OF ALLOGENEIC SC TRANSPLANT IN HEMATOLOGICAL MALIGNANCY PATIENTS USING BUSULFAN 3 (9.6 MG/KG) BASED CONDITIONING REGIMEN
title_sort	outcomes of allogeneic sc transplant in hematological malignancy patients using busulfan 3 (9.6 mg/kg) based conditioning regimen
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/990786919fe843c4b5cddd2870568c6b
work_keys_str_mv	AT majedaltareb outcomesofallogeneicsctransplantinhematologicalmalignancypatientsusingbusulfan396mgkgbasedconditioningregimen AT yazeedbajuaifer outcomesofallogeneicsctransplantinhematologicalmalignancypatientsusingbusulfan396mgkgbasedconditioningregimen AT walidrasheed outcomesofallogeneicsctransplantinhematologicalmalignancypatientsusingbusulfan396mgkgbasedconditioningregimen
_version_	1718440580217831424

OUTCOMES OF ALLOGENEIC SC TRANSPLANT IN HEMATOLOGICAL MALIGNANCY PATIENTS USING BUSULFAN 3 (9.6 MG/KG) BASED CONDITIONING REGIMEN

Ejemplares similares